Please login to the form below

Not currently logged in

New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake


Novartis has presented new data showing Aimovig cuts acute migraine medication days by half in patients who have failed prior preventive therapies.

The results from the STRIVE trial are good news for Novartis and its co-marketer Amgen, who have established Aimovig (erenumab) as the leader in the new class of CGRP inhibitor migraine treatments.

Data from the active treatment phase of STRIVE looked at efficacy and safety of Aimovig (70 and 140 mg) in episodic migraine patients with prior preventive treatment failures.

Trial data shows that 55% of patients on Aimovig 140 mg experienced at least a 50% reduction in the number of monthly migraine days requiring acute medication at week 52.

The study found the total number of monthly migraine days (MMD) cut, as well as migraine-specific medication days (MSMD) for episodic migraine patients who have previously struggled to find effective and tolerable preventive therapies to prevent a migraine.

These results expand the potential scope of Aimovig’s use, and will consolidate its status as the most prescribed anti CGRP.

It has been prescribed to more than 220,000 patients worldwide since launch, and recorded $59m in sales in the first quarter of this year.

The data will be presented at the European Academy of Neurology's (EAN) annual meeting in Oslo, Norway.

Other contenders in the class are Eli Lilly’s Emgality and Teva’s migraine prevention drug Ajovy.

Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It predicts Emgality could hit $1.2bn by this time, with Ajovy forecast to reach $962m.

Lilly recently scored a success with FDA approval in the adjacent indication of cluster headaches.

However the successful launch of the drug has been overshadowed by a falling out between Novartis and Amgen.

In April, it emerged that Amgen was seeking to terminate its co-marketing agreement and seek damages from Novartis, claiming the Swiss pharma company was working with Alder Biopharmaceuticals on a potential rival to Aimovig.

Novartis dismisses this allegation, saying this alliance is no longer live, and claims Amgen is seeking to end the deal in order to reclaim complete control of the drug, including its global revenues.

Article by
Andrew McConaghie

1st July 2019

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....